BioPharma Dive - Latest News

New Amgen obesity drug data disappoint Wall Street

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss effects that weren’t as strong as previously reported.

Jun 24, 2025 - 17:45
 0
New Amgen obesity drug data disappoint Wall Street

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss effects that weren’t as strong as previously reported.

Read More

Tags:

Previous Article

Cassidy calls for delay to CDC vaccine meeting, challenging RFK Jr.

Next Article

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug

Related Posts

FDA’s AI tool ‘Elsa’ is here, and the industry has questions

FDA’s AI tool ‘Elsa’ is here, and the industry has ques...

Jun 6, 2025  0

Intellia filing spurs safety concerns over CRISPR drug

Intellia filing spurs safety concerns over CRISPR drug

May 29, 2025  0

At ASCO, Enhertu cements growing role in stomach cancer care

At ASCO, Enhertu cements growing role in stomach cancer...

May 31, 2025  0